Targeted deletion of ERK2 in cardiomyocytes attenuates hypertrophic response but provokes pathological stress induced cardiac dysfunction

Journal of Molecular and Cellular Cardiology

Volumn 72, Issue , 2014, Pages 104-116

  Ulm, Susanne ^a   Liu, Wei ^a   Zi, Min ^b   Tsui, Hoyee ^a   Chowdhury, Sanjoy K ^a   Endo, Shogo ^c   Satoh, Yasushi ^d   Prehar, Sukhpal ^b   Wang, Ruoxi ^a   Cartwright, Elizabeth J ^b   Wang, Xin ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Apoptosis; Cardiac hypertrophy; Genetically modified mice; Interstitial fibrosis; Signal transduction

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MAPK1 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATRIAL NATRIURETIC PEPTIDE GENE; BETA ADRENERGIC STIMULATION; BRAIN NATRIURETIC PEPTIDE GENE; CONTROLLED STUDY; DETERIORATION; DOWN REGULATION; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SWIMMING; ANIMAL; CARDIOMEGALY; DEFICIENCY; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; PRIMARY CELL CULTURE;

ANIMALS; APOPTOSIS; ATRIAL NATRIURETIC FACTOR; CARDIOMEGALY; FIBROSIS; GENE EXPRESSION REGULATION; MALE; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIUM; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; PRIMARY CELL CULTURE; STRESS, PHYSIOLOGICAL; SWIMMING;

EID: 84901194057     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.03.002     Document Type: Article

References (44)

1. Hill J.A., Olson E.N. Cardiac plasticity. N Engl J Med 2008, 358:1370-1380.
2. Maron B.J. Hypertrophic cardiomyopathy in childhood. Pediatr Clin North Am 2004, 51:1305-1346.
3. Ogata T., Yoshida R. PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes. Pediatr Endocrinol Rev 2005, 2:669-674.
4. Burch M., Sharland M., Shinebourne E., Smith G., Patton M., McKenna W. Cardiologic abnormalities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol 1993, 22:1189-1192.
5. Tartaglia M., Mehler E.L., Goldberg R., Zampino G., Brunner H.G., Kremer H., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001, 29:465-468.
6. Araki T., Mohi M.G., Ismat F.A., Bronson R.T., Williams I.R., Kutok J.L., et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 2004, 10:849-857.
7. Fragale A., Tartaglia M., Wu J., Gelb B.D. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 2004, 23:267-277.
8. Nakamura T., Colbert M., Krenz M., Molkentin J.D., Hahn H.S., Dorn G.W., et al. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest 2007, 117:2123-2132.
9. Krenz M., Gulick J., Osinska H.E., Colbert M.C., Molkentin J.D., Robbins J. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome. Proc Natl Acad Sci U S A 2008, 105:18930-18935.
10. Kontaridis M.I., Swanson K.D., David F.S., Barford D., Neel B.G. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 2006, 281:6785-6792.
11. Hanna N., Montagner A., Lee W.H., Miteva M., Vidal M., Vidaud M., et al. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett 2006, 580:2477-2482.
12. Marin T.M., Keith K., Davies B., Conner D.A., Guha P., Kalaitzidis D., et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest 2011, 121:1026-1043.
13. Wellbrock C., Karasarides M., Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004, 5:875-885.
14. Harris I.S., Zhang S., Treskov I., Kovacs A., Weinheimer C., Muslin A.J. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 2004, 110:718-723.
15. Yamaguchi O., Watanabe T., Nishida K., Kashiwase K., Higuchi Y., Takeda T., et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 2004, 114:937-943.
16. Kehat I., Molkentin J.D. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann N Y Acad Sci 2010, 1188:96-102.
17. Lips D.J., Bueno O.F., Wilkins B.J., Purcell N.H., Kaiser R.A., Lorenz J.N., et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 2004, 109:1938-1941.
18. Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.A., Kimball T.R., Klevitsky R., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000, 19:6341-6350.
19. Maillet M., Purcell N.H., Sargent M.A., York A.J., Bueno O.F., Molkentin J.D. DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility. J Biol Chem 2008, 283:31246-31255.
20. Bueno O.F., Molkentin J.D. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 2002, 91:776-781.
21. Purcell N.H., Wilkins B.J., York A., Saba-El-Leil M.K., Meloche S., Robbins J., et al. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A 2007, 104:14074-14079.
22. Pages G., Guerin S., Grall D., Bonino F., Smith A., Anjuere F., et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999, 286:1374-1377.
23. Hatano N., Mori Y., Oh-hora M., Kosugi A., Fujikawa T., Nakai N., et al. Essential role for ERK2 mitogen-activated protein kinase in placental development. Genes Cells 2003, 8:847-856.
24. Satoh Y., Endo S., Nakata T., Kobayashi Y., Yamada K., Ikeda T., et al. ERK2 contributes to the control of social behaviors in mice. J Neurosci 2011, 31:11953-11967.
25. Liu W., Zi M., Jin J., Prehar S., Oceandy D., Kimura T.E., et al. Cardiac-specific deletion of Mkk4 reveals its role in pathological hypertrophic remodeling, but not in physiological cardiac growth. Circ Res 2009, 104:905-914.
26. Liu W., Zi M., Naumann R., Ulm S., Jin J., Taglieri D.M., et al. Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart. Circulation 2011, 124:2702-2715.
27. Livak K.L., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-δδCT method. Methods 2001, 25:402-408.
28. Kehat I., Davis J., Tiburcy M., Accornero F., Saba-El-Leil M.K., Maillet M., et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res 2011, 108:176-183.
29. Sbroggio M., Carnevale D., Bertero A., Cifelli G., De Blasio E., Mascio G., et al. IQGAP1 regulates ERK1/2 and AKT signalling in the heart and sustains functional remodelling upon pressure overload. Cardiovasc Res 2011, 91:456-464.
30. Lorenz K., Schmitt J.P., Schmitteckert E.M., Lohse M.J. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 2009, 15:75-83.
31. Walsh K. Akt signaling and growth of the heart. Circulation 2006, 113:2032-2034.
32. Ellison G.M., Waring C.D., Vicinanza C., Torella D. Physiological cardiac remodelling in response to endurance exercise training: cellular and molecular mechanisms. Heart 2012, 98:5-10.
33. Bostrom P., Mann N., Wu J., Quintero P.A., Plovie E.R., Panakova D., et al. C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 2010, 143:1072-1083.
34. Molkentin J.D. The transcription factor C/EBPbeta serves as a master regulator of physiologic cardiac hypertrophy. Circ Res 2011, 108:277-278.
35. Bersell K., Arab S., Haring B., Kuhn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009, 138:257-270.
36. Moelling K., Schad K., Bosse M., Zimmermann S., Schweneker M. Regulation of Raf-Akt cross-talk. J Biol Chem 2002, 277:31099-31106.
37. Roskoski R. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 2012, 66:105-143.
38. Allan L.A., Morrice N., Brady S., Magee G., Pathak S., Clarke P.R. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 2003, 5:647-654.
39. Balmanno K., Cook S.J. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009, 16:368-377.
40. Qin J., Xin H., Nickoloff B.J. Specifically targeting ERK1 or ERK2 kills melanoma cells. J Transl Med 2012, 10:15.
41. Chen M.M., Lam A., Abraham J.A., Schreiner G.F., Joly A.H. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000, 32:1805-1819.
42. Van Oort R.J., van Rooij E., Bourajjaj M., Schimmel J., Jansen M.A., van der Nagel R., et al. MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure. Circulation 2006, 114:298-308.
43. Radhakrishnan S.S., Blalock T.D., Robinson P.M., Secker G., Daniels J., Grotendorst G.R., et al. Effect of connective tissue growth factor on protein kinase expression and activity in human corneal fibroblasts. Invest Ophthalmol Vis Sci 2012, 53:8076-8085.
44. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.